Editorial

← vista completa

Published on July 22, 2016 | http://doi.org/10.5867/medwave.2016.06.6504

Prostate cancer screening

Tamizaje en cáncer de próstata

Arquímedes Rodríguez-Carlin , Octavio Castillo

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Arquímedes Rodríguez-Carlin

dr.octaviocastillo@gmail.com

Octavio Castillo

Figures

Article has no figures.

Forum

No messages

History

Citation Rodríguez-Carlin A, Castillo O. Prostate cancer screening. Medwave 2016;16(06):e6504 doi: 10.5867/medwave.2016.06.6504

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 22/07/2016

Index

Metrics

Not available at the moment.

Notes

References

  1. Departamento de estadísticas e información de salud, Ministerio de Salud, Gobierno de Chile, Defunciones y mortalidad por causas. Santiago, Chile: MINSAL; 2014 [on line]. | Link
  2. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. | CrossRef | PubMed
  3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012 Mar 15;366(11):981-90. | CrossRef | PubMed
  4. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS. National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology. 1998 Sep;52(3):444-8; discussion 448-9. | PubMed
  5. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999 Oct;17(10):3167-72. | PubMed
  6. Koulikov D, Mamber A, Fridmans A, Abu Arafeh W, Shenfeld OZ. Why I cannot find the prostate? Behind the subjectivity of rectal exam. ISRN Urol. 2012;2012:456821. | CrossRef
  7. Cui T, Kovell RC, Terlecki RP. Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature. Curr Med Res Opin. 2016 Jul;4:1-7. [Epub ahead of print]
  8. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012 Jul 17;157(2):120-34. | CrossRef | PubMed
  9. American Urological Association. Early detection of prostate cancer: AUA guideline. [on line] | Link
  10. Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010 Mar;183(3):963-8. | CrossRef | PubMed
  11. Jemal A, Fedewa SA, Ma J, Siegel R, Lin CC, Brawley O, et al. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. JAMA. 2015 Nov 17;314(19):2054-61. | CrossRef | PubMed
  12. Gulati R, Tsodikov A, Etzioni R, Hunter-Merrill RA, Gore JL, Mariotto AB, et al. Expected population impacts of discontinued prostate-specific antigen screening. Cancer. 2014 Nov 15;120(22):3519-26. | CrossRef | PubMed